Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.49 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.46 |
| ▸ | CETP | P11597 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GMNN | O75496 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | CXCR5 | P32302 | 2/20 | 0.45 |
| ▸ | CCR6 | P51684 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 2/20 | 0.45 |
| ▸ | UBE2N | P61088 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL254521 | 1.00 | DGKA (0.49) | DGKASPHK2SPHK1CETPMEN1 | |
| SCHEMBL12735352 | 0.95 | FAAH (0.50) | DGKAALDH1A1LMNAALOX15FAAH | |
| SCHEMBL30469 | 0.95 | FAAH (0.50) | DGKAALDH1A1LMNAALOX15FAAH | |
| SCHEMBL16694673 | 0.95 | FAAH (0.50) | DGKAALDH1A1LMNAALOX15FAAH | |
| SCHEMBL12664404 | 0.95 | FAAH (0.50) | DGKAALDH1A1LMNAALOX15FAAH | |
| SCHEMBL1288253 | 0.89 | USP2 (0.46) | SPHK1CETPMEN1MAPTKMT2A | |
| SCHEMBL3673713 | 0.89 | USP2 (0.46) | SPHK1CETPMEN1MAPTKMT2A | |
| SCHEMBL11405257 | 0.89 | USP2 (0.46) | SPHK1CETPMEN1MAPTKMT2A | |
| SCHEMBL1288234 | 0.89 | USP2 (0.46) | SPHK1CETPMEN1MAPTKMT2A | |
| SCHEMBL3669886 | 0.89 | USP2 (0.46) | SPHK1CETPMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 509 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022115739-A1 | — | — | 2022-06-02 | — | — | WO | claimed |
| EP-4735033-A2 | MRNA-ENCODED TAT WITH ATTENUATED CYTOTOXICITY FOR HIV AND SIV LATENCY REVERSAL | The Trustees of the University of Pennsylvania (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025128913-A1 | INHIBITION OF ENDOSOMAL ESCAPE DETECTION TO AMELIORATE THE INFLAMMATORY SIDE-EFFECTS OF LIPID NANOPARTICLES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025129106-A1 | IMMUNOEVASIVE TARGETING MOLECULES FOR EFFICIENT TARGETED DELIVERY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025111442-A1 | LIPID NANOPARTICLES AND METHODS OF USE FOR DNA DELIVERY | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025080672-A1 | IMMUNE CELL TARGETED DELIVERY VEHICLES AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-04-17 | — | — | WO | disclosed |
| EP-4531905-A1 | RNA COMPOSITIONS FOR DELIVERY OF MONKEYPOX ANTIGENS AND RELATED METHODS | BioNTech SE (DE) | 2025-04-09 | — | — | EP | disclosed |
| WO-2025072623-A1 | COMPOSITIONS AND METHODS FOR TARGETING IMMUNE CELLS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2025038627-A2 | PENTAERYTHRITOL-BASED IONIZABLE AMPHIPHILIC JANUS DENDRIMERS, DELIVERY SYSTEMS COMPRISING THEREOF, AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-02-20 | — | — | WO | disclosed |
| WO-2025030103-A1 | RNA COMPOSITIONS ENCODING HERPES SIMPLEX VIRUS GLYCOPROTEIN B ANTIGENS AND USES THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-02-06 | — | — | WO | disclosed |
| WO-2011000107-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-01-06 | — | — | WO | disclosed |
| EP-2224912-A1 | IMPROVED COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA Pharmaceuticals Corporation (CA) | 2010-09-08 | — | — | EP | disclosed |
| WO-2010083615-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN C-III EXPRESSION | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010068816-A1 | GNAQ TARGETED DSRNA COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| US-20100130588-A1 | NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2010-05-27 | — | — | US | disclosed |
| WO-2009132131-A1 | AMINO LIPID BASED IMPROVED LIPID FORMULATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009129319-A2 | SILENCING OF CSN5 GENE EXPRESSION USING INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009127060-A1 | NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009088891-A1 | SCREENING METHOD FOR SELECTED AMINO LIPID-CONTAINING COMPOSITIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009086558-A1 | IMPROVED COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130588-A1 | NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY | SARNP, NPC1L1, SNRPE | DGKA 1204/4885SPHK2 177/4885SPHK1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.